GlassScriptPhysician profile
Alonso Victor Pacheco
NPI 1326187311
$5,388.50
in general payments reported to CMS, 2019-2025
15 companies · $26.76 in 2025
The $26.76 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $135 · 2021: $36.31 · 2022: $147 · 2023: $1,209 · 2024: $2,925 · 2025: $26.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,925 · Honoraria: $1,000 · Food and Beverage: $190 · Education: $46.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,925.00 |
| Honoraria | $1,000.00 |
| Food and Beverage | $190.18 |
| Education | $46.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $2,925.00 | 2024 | Brukinsa |
| Pharmaessentia USA Corporation | $1,100.00 | 2023 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $750.00 | 2019 | |
| Dendreon Pharmaceuticals LLC | $338.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $63.42 | 2023 | Tagrisso |
| Pfizer INC. | $56.80 | 2022-2023 | |
| Daiichi Sankyo INC. | $26.98 | 2022 | |
| Janssen Biotech, INC. | $26.76 | 2025 | Rybrevant |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Novocure INC. | $18.52 | 2022 | |
| Genentech USA, INC. | $15.16 | 2020 | |
| Tosoh Bioscience, INC. | $13.00 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2021 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alonso Pacheco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.